Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 185 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Idiopathic Inflammatory Myositis Clear all
Completed Early Phase 1 Interventional

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

NCT00802815
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Etanercept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 7, 2026, 9:48 PM EDT
Completed No phase listed Observational

Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases

NCT00341679
View directory record Official record
Conditions
Autoimmune/Connective Tissue Diseases, Idiopathic Inflammatory Myopathies, Polymyositis, Dermatomyositis
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
2 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate

NCT01150526
View directory record Official record
Conditions
Healthy
Interventions
CaHMB, HMB Free Acid Gel, Placebo, Placebo Gel Dosage
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Oct 7, 2026, 9:48 PM EDT
Recruiting Phase 1 Interventional

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06925542
View directory record Official record
Conditions
SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Interventions
CTX112
Biological
Lead sponsor
CRISPR Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 7, 2026, 9:48 PM EDT
Completed No phase listed Observational

The CARRA Registry

NCT01697254
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 7, 2026, 9:48 PM EDT
Recruiting No phase listed Observational

The Fibrodysplasia Ossificans Progressiva (FOP) Registry

NCT02745158
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Not listed
Lead sponsor
The International FOP Association
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2040
U.S. locations
1
States / cities
North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

NCT03817424
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

NCT01906372
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Adrenocorticotropic Hormone Gel
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Great Neck, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

NCT05099445
View directory record Official record
Conditions
Renal Impairment, Hemodialysis
Interventions
INCB000928
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Rialto, California • Hialeah, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 7, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Silicone-Associated Connective Tissue Diseases

NCT00001330
View directory record Official record
Conditions
Autoimmune Diseases, Connective Tissue Diseases, Scleroderma, Circumscribed, Scleroderma, Systemic
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

NCT02250443
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis (sIBM)
Interventions
BYM338 (Bimagrumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 7, 2026, 9:48 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

A Study In Adults With Moderate To Severe Dermatomyositis

NCT03181893
View directory record Official record
Conditions
Dermatomyositis
Interventions
PF-06823859 low, Placebo Arm, PF-06823859 high
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 7, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 7, 2026, 9:48 PM EDT
Terminated Phase 1 Interventional Results available

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

NCT00278564
View directory record Official record
Conditions
MYOPATHY
Interventions
Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 7, 2026, 9:48 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104
View directory record Official record
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

NCT05027802
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
14 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 7, 2026, 9:48 PM EDT
Recruiting No phase listed Observational

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06089616
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
8 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 9:48 PM EDT
Recruiting No phase listed Observational

Rheumatology Diet Study

NCT06339957
View directory record Official record
Conditions
Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Dermatomyositis/polymyositis, Sjogren's Syndrome, Systemic Lupus Erythematous, Scleroderma, Fibromyalgia
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 7, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular and Fibrosis Imaging Study

NCT01758250
View directory record Official record
Conditions
Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions
Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 7, 2026, 9:48 PM EDT
Recruiting No phase listed Observational

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

NCT07374107
View directory record Official record
Conditions
IBM, IIM, Myositis, Inflammatory Myopathy, Dermatomyositis, Dermatomyositis, Juvenile, Anti-synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Polymyositis, Inclusion Body Myositis, Juvenile Myositis, Juvenile Dermatomyositis
Interventions
No intervention - qualitative and mixed methods investigations
Other
Lead sponsor
Myositis International Health & Research Collaborative Alliance Foundation
Other
Eligibility
7 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Study of Arimoclomol in Inclusion Body Myositis (IBM)

NCT02753530
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol, Placebo
Drug · Other
Lead sponsor
ZevraDenmark
Industry
Eligibility
45 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 7, 2026, 9:48 PM EDT
Terminated Not applicable Interventional

Comparison of Training Load With/Out Blood Flow Restriction Training in Rheumatoid Populations

NCT04309227
View directory record Official record
Conditions
Rheumatoid Arthritis, Myositis, Osteoarthritis, Weakness, Muscle
Interventions
Strength Training
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 7, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

NCT03188666
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
REGN2477, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 7, 2026, 9:48 PM EDT